About David

David’s practice focuses on antitrust and competition law, representing businesses in merger reviews and government investigations before the US Department of Justice (DOJ) and the Federal Trade Commission (FTC), and in antitrust litigation. He has particular experience working on pharmaceutical and tech matters and complex issues at the intersection of antitrust and intellectual property law.

View full bio

Experience

Mabwell Bioscience Announces Formation of Kalexo Bio With Aditum Bio

Mabwell Bioscience Announces Formation of Kalexo Bio With Aditum Bio

September 17, 2025

Cooley advised Mabwell Bioscience, an innovation-driven biopharmaceutical company with capabilities spanning the entire pharmaceutical value chain, on its exclusive license agreement with Aditum Bio to launch Kalexo Bio, a new company formed in conjunction with an exclusive global license agreement to develop 2MW7141, a novel dual-target small interfering RNA (siRNA) candidate for lipid management in patients with dyslipidemia and for the prevention of high-risk atherosclerotic cardiovascular disease events.

Read more

Related contacts

Charity Williams
Partner, San Diego
Freddy Yip
Associate, Hong Kong
Ken Rollins
Partner in Charge – San Diego, San Diego
Brett Dovman
Associate, San Diego
Jeffrey J. Tolin
Partner, New York
Amanda Pacheco
Associate, Palo Alto
Andrew Epstein
Special Counsel, Seattle
Zhijing Yu
Associate, Singapore
Christopher Kimball
Partner, Washington, DC
David Burns
Special Counsel, Washington, DC
Robert Eisenbach
Of Counsel, San Francisco
Rachel Thorn
Of counsel, New York
Natasha Leskovsek
Of Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC

Related Practices & Industries

Life Sciences Corporate Partnering and Licensing
Life Sciences
Healthcare
Emerging Companies
Tax
Cyber/Data/Privacy
Antitrust and Competition
CFIUS
Business Restructuring
Commercial Litigation
Life Sciences and Healthcare Regulatory
Export Controls and Economic Sanctions
CooleyREG

Hengrui Pharma and Braveheart Bio Enter Into Exclusive License Agreement

Hengrui Pharma and Braveheart Bio Enter Into Exclusive License Agreement

September 5, 2025

Cooley advised Hengrui Pharma, a global pharmaceutical company, on its exclusive license agreement with Braveheart Bio for HRS-1893, a small-molecule inhibitor of cardiac myosin independently developed by Hengrui Pharma with best-in-class potential.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Freddy Yip
Associate, Hong Kong
Steve Przesmicki
Partner, San Diego
Navya Dasari
Associate, New York
Max Levinbook
Associate, San Diego
Jeffrey J. Tolin
Partner, New York
Amanda Pacheco
Associate, Palo Alto
David Burns
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Zhijing Yu
Associate, Singapore
Christopher Kimball
Partner, Washington, DC
Robert Eisenbach
Of Counsel, San Francisco
Rachel Thorn
Of counsel, New York
Karen Tsai
Special Counsel, Washington, DC

Related Practices & Industries

Life Sciences Corporate Partnering and Licensing
Life Sciences
Healthcare
Biotechnology
Tax
Antitrust and Competition
Cyber/Data/Privacy
CFIUS
Business Restructuring
Commercial Litigation
Asia

Argo Biopharma Announces Multi-Asset License and Option Agreements With Novartis

Argo Biopharma Announces Multi-Asset License and Option Agreements With Novartis

September 3, 2025

Cooley advised Argo Biopharma, a clinical-stage biotechnology company focused on developing next-generation small interfering RNA (siRNA) therapeutics, on its additional strategic collaboration with Novartis for multiple cardiovascular assets in Argo’s pipeline.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Jennifer Raab
Partner, Palo Alto
Freddy Yip
Associate, Hong Kong
Yuhan Wu
Associate, Palo Alto
Aaron Pomeroy
Partner, Colorado
Amanda Pacheco
Associate, Palo Alto
Julia R. Brinton
Special Counsel, Washington, DC
David Burns
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Mari Dugas
Associate, Washington, DC
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Patrick Loofbourrow
Partner, Singapore
Phil Mitchell
Partner, New York
Bin Wang
Special Counsel, Palo Alto

Related Practices & Industries

Life Sciences Corporate Partnering and Licensing
Biotechnology
Life Sciences
Healthcare
Tax
Antitrust and Competition
Cyber/Data/Privacy
Asia
Life Sciences and Healthcare Regulatory

Hengrui Pharma and GSK Enter Agreement to Develop up to 12 Medicines

Hengrui Pharma and GSK Enter Agreement to Develop up to 12 Medicines

July 27, 2025

Cooley advised Hengrui Pharma, a global pharmaceutical company, on its up to $12.5 billion agreement with GSK to develop up to 12 medicines to complement GSKs extensive respiratory, immunology and inflammation (RI&I) and oncology pipeline.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Frances Stocks Allen
Partner, London
Jiqiang Lin
Associate, New York
Freddy Yip
Associate, Hong Kong
Aaron Pomeroy
Partner, Colorado
David Wilson
Partner, London
Dr. Xiaozhen (Shawn) Yu
Partner, Washington, DC
Julia R. Brinton
Special Counsel, Washington, DC
David Burns
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Robert Eisenbach
Of Counsel, San Francisco
Navya Dasari
Associate, New York
Rick Jantz
Associate, Santa Monica
Eerik Kukebal
Associate, London
Daniel Millard
Associate, London
Patrick Sharma
Associate, Santa Monica
Zhijing Yu
Associate, Singapore

Related Practices & Industries

Life Sciences Corporate Partnering and Licensing
Life Sciences
Healthcare
Biotechnology
Life Sciences and Healthcare Regulatory
Tax
Cyber/Data/Privacy
Business Restructuring
Antitrust and Competition
Patent Counseling and Prosecution
Asia

Cooley Represents 3SBio on Antitrust Aspects of Its Exclusive Licensing Agreement With Pfizer

Cooley Represents 3SBio on Antitrust Aspects of Its Exclusive Licensing Agreement With Pfizer

July 24, 2025

Cooley advised 3SBio, a leading Chinese biopharmaceutical company, on antitrust aspects of its up to $6 billion+ exclusive licensing agreement with Pfizer for the development, manufacture and commercialization of SSGJ-707, a bispecific antibody targeting programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF).

Read more

Related contacts

David Burns
Special Counsel, Washington, DC
Megan Browdie
Partner, Washington, DC
Rubin Waranch
Associate, Colorado

Related Practices & Industries

Antitrust and Competition
Healthcare
Biotechnology
Life Sciences and Healthcare Regulatory
View more

Admissions and credentials

District of Columbia

Vermont

Virginia

Rankings and accolades

Super Lawyers Rising Stars: Antitrust (2018-2022)

Best Lawyers: Antitrust Law, Ones to Watch

Legal 500: Merger Control (2021)

Memberships and affiliations

American Bar Association (ABA)

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.